Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002365.SZ Stock Summary
Top 10 Correlated ETFs
002365.SZ
In the News
002365.SZ Financial details
Company Rating
Neutral
Market Cap
2.2B
Income
24.36M
Revenue
1.14B
Book val./share
7.27
Cash/share
3.27
Dividend
0.1
Dividend %
1.03%
Employees
1K
Optionable
No
Shortable
Yes
Earnings
24 Apr 2021
P/E
118.84
Forward P/E
-
PEG
-15.15
P/S
2.52
P/B
1.42
P/C
2.25
P/FCF
-1035.89
Quick Ratio
4.29
Current Ratio
4.6
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
0.08
EPS next Y
-
EPS next Q
-
EPS this Y
26.32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-4.99%
Revenue last 5Y
7.78%
Revenue Q/Q
-16.05%
EPS Q/Q
-124.64%
-
-
-
-
SMA20
-
SMA50
-30%
SMA100
-30%
Inst Own
-
Inst Trans
-
ROA
1%
ROE
1%
ROC
0.02%
Gross Margin
34%
Oper. Margin
4%
Profit Margin
2%
Payout
158%
Shs Outstand
294.68M
Shs Float
266.83M
-
-
-
-
Target Price
-
52W Range
5.45-11.83
52W High
-33.09%
52W Low
+47.2%
RSI
48
Rel Volume
0.87
Avg Volume
4.57M
Volume
3.97M
Perf Week
-2.26%
Perf Month
30.04%
Perf Quarter
-
Perf Half Y
-27.06%
-
-
-
-
Beta
0.24
-
-
Volatility
0.16%, 0.33%
Prev Close
2.08%
Price
7.36
Change
1.66%
002365.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.47 | 4.74 | 4.07 | 5.46 | 4.97 | |
Net income per share | 0.62 | 0.31 | 0.37 | 0.39 | 0.48 | |
Operating cash flow per share | 1.08 | 0.83 | 0.72 | 0.36 | 1.32 | |
Free cash flow per share | 0.15 | 0.36 | 0.35 | 0.14 | 0.81 | |
Cash per share | 0.2 | 1.74 | 2.59 | 1.91 | 2.83 | |
Book value per share | 5.46 | 5.58 | 6.09 | 6.51 | 6.85 | |
Tangible book value per share | 5.21 | 5.39 | 5.95 | 6.49 | 6.83 | |
Share holders equity per share | 5.46 | 5.58 | 6.09 | 6.51 | 6.85 | |
Interest debt per share | 0.01 | 0.01 | 0.43 | 0.08 | 0.14 | |
Market cap | 2.92B | 2.85B | 2.71B | 3.04B | 3.09B | |
Enterprise value | 2.9B | 2.74B | 2.71B | 2.97B | 2.86B | |
P/E ratio | 16.34 | 31.71 | 25.63 | 27.3 | 22.02 | |
Price to sales ratio | 2.9 | 2.08 | 2.31 | 1.94 | 2.11 | |
POCF ratio | 9.29 | 11.91 | 13.09 | 29.88 | 7.98 | |
PFCF ratio | 65.55 | 27.12 | 26.46 | 78.47 | 12.97 | |
P/B Ratio | 1.85 | 1.77 | 1.54 | 1.63 | 1.53 | |
PTB ratio | 1.85 | 1.77 | 1.54 | 1.63 | 1.53 | |
EV to sales | 2.88 | 2 | 2.31 | 1.9 | 1.95 | |
Enterprise value over EBITDA | 9.83 | 11.05 | 10.26 | 11.25 | 8.94 | |
EV to operating cash flow | 9.23 | 11.43 | 13.13 | 29.16 | 7.37 | |
EV to free cash flow | 65.08 | 26.04 | 26.54 | 76.59 | 11.99 | |
Earnings yield | 0.06 | 0.03 | 0.04 | 0.04 | 0.05 | |
Free cash flow yield | 0.02 | 0.04 | 0.04 | 0.01 | 0.08 | |
Debt to equity | 0 | 0 | 0.07 | 0.01 | 0.02 | |
Debt to assets | 0 | 0 | 0.06 | 0.01 | 0.02 | |
Net debt to EBITDA | -0.07 | -0.46 | 0.03 | -0.28 | -0.73 | |
Current ratio | 2.79 | 3.64 | 3.31 | 3.63 | 4.19 | |
Interest coverage | 29.28K | 408.95 | 111.4 | 53.93 | 229.38 | |
Income quality | 1.76 | 2.24 | 1.74 | 0.86 | 2.92 | |
Dividend Yield | 0.01 | 0.01 | 0.02 | 0.01 | 0 | |
Payout ratio | 0.11 | 0.33 | 0.43 | 0.28 | 0.01 | |
Sales general and administrative to revenue | 0.01 | 0.02 | 0.02 | 0.02 | 0.06 | |
Research and developement to revenue | 0.02 | 0.04 | 0.04 | 0.03 | 0.03 | |
Intangibles to total assets | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | |
Capex to operating cash flow | -0.86 | -0.56 | -0.51 | -0.62 | -0.38 | |
Capex to revenue | -0.27 | -0.1 | -0.09 | -0.04 | -0.1 | |
Capex to depreciation | -3.38 | -1.19 | -0.92 | -0.54 | -1.21 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0 | |
Graham number | 8.7 | 6.25 | 7.08 | 7.54 | 8.58 | |
ROIC | 0.11 | 0.07 | 0.06 | 0.06 | 0.06 | |
Return on tangible assets | 0.1 | 0.05 | 0.05 | 0.05 | 0.06 | |
Graham Net | -0.33 | 1.43 | 2.03 | 1.98 | 2.51 | |
Working capital | 492.18M | 549.14M | 717.31M | 772.52M | 910.22M | |
Tangible asset value | 1.51B | 1.56B | 1.72B | 1.86B | 2.01B | |
Net current asset value | 443.82M | 505.9M | 677.62M | 736.94M | 874.17M | |
Invested capital | 0 | 0 | 0.07 | 0.01 | 0.02 | |
Average receivables | 169.88M | 155.87M | 172.86M | 282.34M | 285.46M | |
Average payables | 95.15M | 126.76M | 104.37M | 106.24M | 138.84M | |
Average inventory | 88.93M | 100.74M | 92.9M | 113.72M | 147.69M | |
Days sales outstanding | 59.14 | 39.64 | 61.27 | 85.76 | 50.69 | |
Days payables outstanding | 79.29 | 38.58 | 43.62 | 34.75 | 60.58 | |
Days of inventory on hand | 54.22 | 36.14 | 36.51 | 44.09 | 55.67 | |
Receivables turnover | 6.17 | 9.21 | 5.96 | 4.26 | 7.2 | |
Payables turnover | 4.6 | 9.46 | 8.37 | 10.5 | 6.03 | |
Inventory turnover | 6.73 | 10.1 | 10 | 8.28 | 6.56 | |
ROE | 0.11 | 0.06 | 0.06 | 0.06 | 0.07 | |
Capex per share | -0.93 | -0.46 | -0.36 | -0.22 | -0.51 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.99 | 1.14 | 1.06 | 0.91 | 0.8 | |
Net income per share | 0.15 | -0.07 | 0.05 | 0.14 | -0.03 | |
Operating cash flow per share | 0.15 | -0.07 | 0.05 | 0.38 | 0.13 | |
Free cash flow per share | 0 | -0.3 | -0.07 | 0.31 | 0.06 | |
Cash per share | 2.51 | 2.8 | 2.8 | 3.11 | 3.27 | |
Book value per share | 6.82 | 6.79 | 6.9 | 6.97 | 7.27 | |
Tangible book value per share | 6.79 | 6.76 | 6.87 | 6.95 | 7.22 | |
Share holders equity per share | 6.82 | 6.79 | 6.9 | 6.97 | 7.27 | |
Interest debt per share | 0.03 | 0.13 | 0.03 | 0.03 | 0.04 | |
Market cap | 3.11B | 3.12B | 3.24B | 2.87B | 2.88B | |
Enterprise value | 3.01B | 2.89B | 3.04B | 2.61B | 2.61B | |
P/E ratio | 17.27 | -35.35 | 54.04 | 17.42 | -74.13 | |
Price to sales ratio | 10.51 | 9.2 | 10.41 | 10.73 | 12.82 | |
POCF ratio | 69.09 | -141.4 | 216.15 | 25.9 | 81.53 | |
PFCF ratio | -7.93K | -34.58 | -161.92 | 31.17 | 186.05 | |
P/B Ratio | 1.53 | 1.55 | 1.59 | 1.4 | 1.41 | |
PTB ratio | 1.53 | 1.55 | 1.59 | 1.4 | 1.41 | |
EV to sales | 10.18 | 8.5 | 9.78 | 9.77 | 11.63 | |
Enterprise value over EBITDA | 65.25 | 170.38 | 622.07 | 56.88 | 420.96 | |
EV to operating cash flow | 66.9 | -130.77 | 203.15 | 23.58 | 73.99 | |
EV to free cash flow | -7.68K | -31.98 | -152.18 | 28.37 | 168.84 | |
Earnings yield | 0.01 | -0.01 | 0 | 0.01 | 0 | |
Free cash flow yield | 0 | -0.03 | -0.01 | 0.03 | 0.01 | |
Debt to equity | 0 | 0.02 | 0 | 0 | 0 | |
Debt to assets | 0 | 0.02 | 0 | 0 | 0 | |
Net debt to EBITDA | -2.14 | -13.86 | -39.8 | -5.61 | -42.9 | |
Current ratio | 5.66 | 4.19 | 4.34 | 4.31 | 4.6 | |
Interest coverage | 1.19K | -358.36 | 179.38 | 886.2 | 15.26 | |
Income quality | 1 | 1 | 1 | 2.69 | -3.64 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0.01 | |
Payout ratio | 0 | -0.05 | 0.01 | 0 | -3.82 | |
Sales general and administrative to revenue | 0.17 | 0.06 | 0.11 | -0.07 | 0.43 | |
Research and developement to revenue | 0.04 | 0.02 | 0.03 | 0.05 | 0.06 | |
Intangibles to total assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
Capex to operating cash flow | -1.01 | 3.09 | -2.33 | -0.17 | -0.56 | |
Capex to revenue | -0.15 | -0.2 | -0.11 | -0.07 | -0.09 | |
Capex to depreciation | -1.44 | -2.16 | -1.04 | -0.55 | 0.29 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 4.81 | 3.37 | 2.81 | 4.68 | 2.38 | |
ROIC | 0.02 | -0.01 | 0.01 | 0.02 | 0 | |
Return on tangible assets | 0.02 | -0.01 | 0.01 | 0.02 | 0 | |
Graham Net | 2.65 | 2.48 | 2.56 | 2.72 | 2.89 | |
Working capital | 975.71M | 910.22M | 928.68M | 931.44M | 948.16M | |
Tangible asset value | 2.03B | 2.01B | 2.03B | 2.05B | 2.03B | |
Net current asset value | 944.89M | 874.17M | 892.91M | 897.9M | 904.8M | |
Invested capital | 0 | 0.02 | 0 | 0 | 0 | |
Average receivables | 309.17M | 233.35M | 211.27M | 217.58M | 212.41M | |
Average payables | 103.8M | 126.23M | 179.59M | 168.77M | 147.33M | |
Average inventory | 169.26M | 160.58M | 153.18M | 119.11M | 81.72M | |
Days sales outstanding | 80.08 | 53.87 | 63.47 | 72.65 | 83.86 | |
Days payables outstanding | 41.82 | 76.22 | 80.13 | 74.24 | 83.41 | |
Days of inventory on hand | 80.01 | 70.05 | 63.95 | 42.85 | 44.53 | |
Receivables turnover | 1.12 | 1.67 | 1.42 | 1.24 | 1.07 | |
Payables turnover | 2.15 | 1.18 | 1.12 | 1.21 | 1.08 | |
Inventory turnover | 1.12 | 1.28 | 1.41 | 2.1 | 2.02 | |
ROE | 0.02 | -0.01 | 0.01 | 0.02 | 0 | |
Capex per share | -0.15 | -0.23 | -0.12 | -0.06 | -0.07 |
002365.SZ Frequently Asked Questions
What is Qianjiang Yongan Pharmaceutical Co., Ltd. stock symbol ?
Qianjiang Yongan Pharmaceutical Co., Ltd. is a CN stock and trading under the symbol 002365.SZ
What is Qianjiang Yongan Pharmaceutical Co., Ltd. stock quote today ?
Qianjiang Yongan Pharmaceutical Co., Ltd. stock price is $7.36 today.
Is Qianjiang Yongan Pharmaceutical Co., Ltd. stock public?
Yes, Qianjiang Yongan Pharmaceutical Co., Ltd. is a publicly traded company.